NTLA Competitors & Alternatives

Compare Intellia Therapeutics Inc with similar stocks in the same industry

Biotechnology

NTLA

Main Stock
$10.00
+3.09%
Tradestie Score
49
Market Cap
$2.01B
Revenue Growth
-48.0%
Analyst Upside
+127.8%

Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)

Bottleneck Score: 6/10 Genomics Precision Med Gene Editing
Competitive Moat: None
Core Technology Stack: CRISPR/Cas9 gene editing, lipid nanoparticle delivery, in vivo editing platforms
Major Customers 4
future patients with genetic diseases healthcare providers research institutions pharma partners
Critical Suppliers 4
CRISPR IP licensors lipid nanoparticle manufacturers CROs for clinical trials sequencing service providers
Direct Ecosystem Rivals 4

Top Competitors

217 stocks in Biotechnology
Company Price Market Cap P/E Score Action
VCEL Vericel Corporation
$57.27
+0.54%
$1.56B 90.3 35 Compare
DNTH Dianthus Therapeutics, Inc. Common Stock
$88.58
-3.52%
$1.55B - 32 Compare
HRMY Harmony Biosciences Holdings, Inc. Common Stock
$33.13
-1.87%
$1.55B 11.2 57 Compare
PHVS Pharvaris N.V. Ordinary Shares
$32.61
-2.25%
$1.55B - 44 Compare
NVAX Novavax Inc
$8.03
-5.81%
$1.54B - 55 Compare
AUPH Aurinia Pharmaceuticals Inc
$15.48
-1.62%
$1.50B 7.0 56 Compare
GPCR Structure Therapeutics Inc. American Depositary Shares
$18.67
-6.65%
$1.50B - 42 Compare
AMLX Amylyx Pharmaceuticals, Inc. Common Stock
$28.24
-6.78%
$1.49B - 52 Compare
RCUS Arcus Biosciences, Inc.
$16.97
-2.64%
$1.43B - 43 Compare
JANX Janux Therapeutics, Inc. Common Stock
$10.89
-4.22%
$1.42B - 45 Compare

Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2835)

217 stocks in this industry